Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Score, Valuation & Financial Research

Corbus Pharmaceuticals Holdings, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CRBP

Corbus Pharmaceuticals Holdings, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 5.78. These figures are a research snapshot, not a buy or sell recommendation.

What Corbus Pharmaceuticals Holdings, Inc. does

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and strategic financing to fund the research and development of its pipeline of oncology and obesity therapeutic candidates.

Products and services

  • The company is developing a pipeline of clinical-stage drug candidates, including CRB-701 (an antibody drug conjugate targeting Nectin-4), CRB-601 (an anti-integrin monoclonal antibody targeting TGFβ), and CRB-913 (a peripherally restricted CB1 receptor inverse agonist for obesity).

Customer types

Healthcare providers and patients.

Suppliers, materials and equipment

  • Contract Research Organizations and Contract Manufacturing Organizations — The company relies on third-party contract research organizations (CROs) and contract manufacturing organizations (CMOs) for the development, clinical testing, and manufacturing of its product candidates. Specific supplier companies are unnamed. Source

Business relationships and partnerships

  • Jenrin Discovery, LLC — An exclusive license agreement providing Corbus with worldwide rights to develop and market cannabinoid compounds, including CRB-913. Source

Competitors and product-market comparisons

  • Biotechnology and pharmaceutical companies — The company faces competition from various biotechnology and pharmaceutical firms that may develop or commercialize competing products more successfully or faster than Corbus. Source

Business strengths to evaluate

  • Pipeline of innovative scientific approaches to well-understood biological pathways Source

Business risks and research considerations

  • Dependence on third-party contract research and manufacturing organizations Source
  • Significant competition from other biotechnology and pharmaceutical companies Source

Sources: Company research source · Jenrin Discovery, LLC · Pipeline of innovative scientific approaches to well-understood biological pathways

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CRBP financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 5.78
Market capitalization:
107.09M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -101.9M
Free cash flow:
USD -64.5M
Cash:
USD 23.37M
Total debt:
USD 4.26M
EPS:
USD -6.48

What stands out

  • Free cash flow is USD -64.5M, negative for the stored period.
  • The balance sheet shows USD 23.37M of cash versus USD 4.26M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 19.11M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CRBP

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CRBP fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CRBP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CRBP to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CRBP's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CRBP

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.